WO2007014167A3 - Compositions et procedes pour le traitement de maladies epitheliales avec des facteurs de croissance - Google Patents

Compositions et procedes pour le traitement de maladies epitheliales avec des facteurs de croissance Download PDF

Info

Publication number
WO2007014167A3
WO2007014167A3 PCT/US2006/028699 US2006028699W WO2007014167A3 WO 2007014167 A3 WO2007014167 A3 WO 2007014167A3 US 2006028699 W US2006028699 W US 2006028699W WO 2007014167 A3 WO2007014167 A3 WO 2007014167A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
growth factors
treating epithelial
epithelial diseases
Prior art date
Application number
PCT/US2006/028699
Other languages
English (en)
Other versions
WO2007014167A2 (fr
Inventor
Kristen Pierce
Ge Wu
Aileen Zhou
William Roscoe
Stephen Doberstein
Original Assignee
Five Prime Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics, Inc. filed Critical Five Prime Therapeutics, Inc.
Publication of WO2007014167A2 publication Critical patent/WO2007014167A2/fr
Publication of WO2007014167A3 publication Critical patent/WO2007014167A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention a trait à des compositions et procédés pour le traitement de maladies épithéliales telles que la mucosite et la maladie intestinale inflammatoire chez un sujet. L'invention a également trait à des agents thérapeutiques à action prolongée capables de favoriser la survie d'un kératinocyte oral ou d'une cellule épithéliale intestinale.
PCT/US2006/028699 2005-07-22 2006-07-24 Compositions et procedes pour le traitement de maladies epitheliales avec des facteurs de croissance WO2007014167A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70206505P 2005-07-22 2005-07-22
US60/702,065 2005-07-22

Publications (2)

Publication Number Publication Date
WO2007014167A2 WO2007014167A2 (fr) 2007-02-01
WO2007014167A3 true WO2007014167A3 (fr) 2009-09-17

Family

ID=37683889

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/028699 WO2007014167A2 (fr) 2005-07-22 2006-07-24 Compositions et procedes pour le traitement de maladies epitheliales avec des facteurs de croissance

Country Status (1)

Country Link
WO (1) WO2007014167A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3591398A1 (fr) * 2011-08-15 2020-01-08 Children's Hospital Los Angeles Méthodes de criblage d'activateurs de erbb4 qui inhibent l'apoptose de cellules cibles
WO2019231860A1 (fr) * 2018-05-27 2019-12-05 The Board Of Trustees Of The Leland Stanford Junior University Procédé de traitement ou de prévention de la mucosite orale associée à une radiothérapie et à une chimiothérapie utilisant un facteur de croissance de type facteur de croissance épidermique se liant à l'héparine (hb-egf) administré par voie locale
AU2015336008B2 (en) * 2014-10-21 2019-11-21 The Board Of Trustees Of The Leland Stanford Junior University Promoting epithelial regeneration post tonsillectomy using heparin binding epidermal growth factor like growth factor
US10702586B2 (en) 2015-09-28 2020-07-07 Children's Hospital Los Angeles Methods for treating diseases mediated by ErbB4-positive pro-inflammatory macrophages
US20220177533A1 (en) * 2018-08-08 2022-06-09 Sree Chitra Tirunal Institute For Medical Sciences And Technology Recombinant TGF a for wound healing purposes, and the process thereof
US20230145643A1 (en) * 2020-03-31 2023-05-11 Songhomitra Panda-Jonas Agents for use in the therapeutic or prophylactic treatment of retinal pigment epithelium associated diseases

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991012018A1 (fr) * 1990-02-13 1991-08-22 Gropep Pty. Ltd. Procede de traitement de troubles intestinaux
WO1992003155A1 (fr) * 1990-08-24 1992-03-05 Kabi Pharmacia Ab Produit contenant un facteur de croissance et de la glutamine et utilisation d'un facteur de croissance dans le traitement des muqueuses intestinales
WO1996037216A1 (fr) * 1995-05-22 1996-11-28 Genentech, Inc. Procede d'administration de l'igf-i
WO1998011904A1 (fr) * 1996-09-20 1998-03-26 Scientific Hospital Supplies International Limited Prevention du delabrement gastro-intestinal
US6319899B1 (en) * 1997-09-17 2001-11-20 The Nemours Foundation Method and composition for the treatment of inflammatory bowel disease
US20030144202A1 (en) * 1996-10-15 2003-07-31 Amgen Inc. Uses of keratinocyte growth factor-2
US20030171267A1 (en) * 2000-04-12 2003-09-11 Rosen Craig A. Albumin fusion proteins
US20040136952A1 (en) * 2002-12-26 2004-07-15 Mountain View Pharmaceuticals, Inc. Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991012018A1 (fr) * 1990-02-13 1991-08-22 Gropep Pty. Ltd. Procede de traitement de troubles intestinaux
WO1992003155A1 (fr) * 1990-08-24 1992-03-05 Kabi Pharmacia Ab Produit contenant un facteur de croissance et de la glutamine et utilisation d'un facteur de croissance dans le traitement des muqueuses intestinales
WO1996037216A1 (fr) * 1995-05-22 1996-11-28 Genentech, Inc. Procede d'administration de l'igf-i
WO1998011904A1 (fr) * 1996-09-20 1998-03-26 Scientific Hospital Supplies International Limited Prevention du delabrement gastro-intestinal
US20030144202A1 (en) * 1996-10-15 2003-07-31 Amgen Inc. Uses of keratinocyte growth factor-2
US6319899B1 (en) * 1997-09-17 2001-11-20 The Nemours Foundation Method and composition for the treatment of inflammatory bowel disease
US20030171267A1 (en) * 2000-04-12 2003-09-11 Rosen Craig A. Albumin fusion proteins
US20040136952A1 (en) * 2002-12-26 2004-07-15 Mountain View Pharmaceuticals, Inc. Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity

Also Published As

Publication number Publication date
WO2007014167A2 (fr) 2007-02-01

Similar Documents

Publication Publication Date Title
HUS1800021I1 (hu) Humán anti-Il-23 ellenanyagok, készítmények, eljárások és alkalmazások
IL186814A0 (en) Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs and organisms
WO2007007173A3 (fr) Nouveaux anticorps anti-madcam
AU2006279280A8 (en) Methods and compositions for treating neurological disease
WO2006017134A3 (fr) Cellules mesendodermiques et cellules de ligne pre-primitive
EP2197270B8 (fr) Greffons de tissu placentaire et procédés améliorés pour leur préparation et leur utilisation
PT1809303T (pt) Composições farmacêuticas e métodos relacionados para inibir aderências fibrosas ou doença inflamatória com a utilização de fucanos com baixo teor de sulfato
HK1079987A1 (zh) 使用細胞脫唾液酸決定簇和糖綴合物將細胞靶向組織和器官的方法和組合物
IL152127A0 (en) Probiotic compositions for the treatment of inflammatory bowel disease
HK1113689A1 (en) Novel cellular compositions and methods for their preparation
WO2005113747A3 (fr) Systemes de culture tissulaire et organique multicellulaires
IL183435A (en) Lyophilized formulations of keratinocyte growth factor
IL189078A0 (en) Antitumoral bioconjugates of hyaluronic acid or its derivatives obtained by indirect chemical conjugation
WO2007014167A3 (fr) Compositions et procedes pour le traitement de maladies epitheliales avec des facteurs de croissance
EP1791855A4 (fr) Procedes et compositions associes aux proteines argonautes
EP1931390A4 (fr) Compositions et methodes de traitement de maladies auto-immunes
EP1945676A4 (fr) Nouvelles compositions a profils glucidiques tirees de cellules humaines et procedes d'analyse et de modification correspondants
IL190841A0 (en) Pharmaceutical compositions and diagnostic methods for inflammatory skin diseases, disorders or conditions
IL189611A0 (en) Treatment of inflammatory bowel disease
EP1858524A4 (fr) Compositions et methodes de traitement de maladies auto-immunes et de maladies relatives
ZA200805419B (en) Compositions and methods for preventing or treating inflammatory bowel disease
WO2006020430A8 (fr) Nouvelle composition et procedes destines au traitement d'une maladie immunitaire
EP1977003A4 (fr) Méthodes et moyens relatifs à des maladies
WO2005118860A3 (fr) Compositions et procedes contre les inflammations intestinales et utilisations correspondantes
WO2007005659A3 (fr) Procedes et compositions pour cultiver des keratinocytes

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06800289

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06800289

Country of ref document: EP

Kind code of ref document: A2